CA3043667A1 - Methods and compositions for treatment of cartilage damage and arthritis - Google Patents

Methods and compositions for treatment of cartilage damage and arthritis Download PDF

Info

Publication number
CA3043667A1
CA3043667A1 CA3043667A CA3043667A CA3043667A1 CA 3043667 A1 CA3043667 A1 CA 3043667A1 CA 3043667 A CA3043667 A CA 3043667A CA 3043667 A CA3043667 A CA 3043667A CA 3043667 A1 CA3043667 A1 CA 3043667A1
Authority
CA
Canada
Prior art keywords
polypeptide
composition
amino acid
intra
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3043667A
Other languages
English (en)
French (fr)
Inventor
Celeste SCOTTI
Igor Vostiar
Kristen Johnson
Jorg Goldhahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3043667A1 publication Critical patent/CA3043667A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3043667A 2016-11-14 2017-11-13 Methods and compositions for treatment of cartilage damage and arthritis Pending CA3043667A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662421534P 2016-11-14 2016-11-14
US62/421,534 2016-11-14
US201762560301P 2017-09-19 2017-09-19
US62/560,301 2017-09-19
PCT/IB2017/057081 WO2018087727A1 (en) 2016-11-14 2017-11-13 Methods and compositions for treatment of cartilage damage and arthritis

Publications (1)

Publication Number Publication Date
CA3043667A1 true CA3043667A1 (en) 2018-05-17

Family

ID=60629753

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043667A Pending CA3043667A1 (en) 2016-11-14 2017-11-13 Methods and compositions for treatment of cartilage damage and arthritis

Country Status (10)

Country Link
US (3) US11351223B2 (https=)
EP (1) EP3538127A1 (https=)
JP (2) JP2019535707A (https=)
KR (2) KR20190084287A (https=)
CN (2) CN109963579A (https=)
AU (2) AU2017357785A1 (https=)
CA (1) CA3043667A1 (https=)
IL (1) IL266361B2 (https=)
MX (2) MX2019005621A (https=)
WO (1) WO2018087727A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024519893A (ja) 2021-05-24 2024-05-21 ノバルティス アーゲー 変形性関節症の治療方法
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
CN118251594A (zh) * 2021-11-10 2024-06-25 诺华股份有限公司 用于确定angptl多肽的生物活性的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
MXPA05003978A (es) 2002-10-16 2005-06-22 Scripps Research Inst Sintesis de glicoproteinas.
ES2324608T3 (es) 2002-10-16 2009-08-11 The Scripps Research Institute Incorporacion especifica de sitio de cetoaminoacidos en proteinas.
WO2004094593A2 (en) 2003-04-17 2004-11-04 The Scripps Research Institute Expanding the eukaryotic genetic code
US20060160175A1 (en) 2003-07-07 2006-07-20 The Scripps Research Institute Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
WO2005019415A2 (en) 2003-07-07 2005-03-03 The Scripps Research Institute Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
CA2580840A1 (en) 2004-09-21 2006-03-30 The Scripps Research Institute In vivo incorporation of alkynyl amino acids into proteins in eubacteria
EP1807515A4 (en) 2004-10-27 2008-06-18 Scripps Research Inst Orthogonal translation components for the in vivo incorporation of unnatural amino acids
US7960141B2 (en) 2006-03-09 2011-06-14 The Scripps Research Institute Systems for the expression of orthogonal translation components in eubacterial host cells
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
US8858940B2 (en) * 2008-12-10 2014-10-14 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
AU2010273570B2 (en) * 2009-07-14 2014-07-03 Novartis Ag Mesenchymal stem cell differentiation
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
JO3564B1 (ar) * 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) * 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
ES2900815T3 (es) * 2013-03-15 2022-03-18 Scripps Research Inst Compuestos y métodos para inducir la condrogénesis
EP3143026B1 (en) * 2014-05-13 2024-07-10 Novartis AG Compounds and compositions for inducing chondrogenesis

Also Published As

Publication number Publication date
AU2020281098B2 (en) 2024-05-02
IL266361B1 (en) 2023-10-01
EP3538127A1 (en) 2019-09-18
JP2023039962A (ja) 2023-03-22
US20250302915A1 (en) 2025-10-02
CN109963579A (zh) 2019-07-02
WO2018087727A1 (en) 2018-05-17
KR20190084287A (ko) 2019-07-16
IL266361A (en) 2019-06-30
MX2022011897A (es) 2022-10-18
US11351223B2 (en) 2022-06-07
MX2019005621A (es) 2019-08-12
US20220331398A1 (en) 2022-10-20
CN117860868A (zh) 2024-04-12
AU2020281098A1 (en) 2021-01-14
RU2019117884A (ru) 2020-12-14
IL266361B2 (en) 2024-02-01
JP2019535707A (ja) 2019-12-12
RU2019117884A3 (https=) 2021-02-05
KR20240045351A (ko) 2024-04-05
AU2017357785A2 (en) 2019-05-02
AU2017357785A1 (en) 2019-04-11
US20190269754A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
US11179442B2 (en) Peptides and compositions for treatment of joint damage
US20250302915A1 (en) Methods and compositions for treatment of cartilage damage and arthritis
US20220402987A1 (en) Peptides and compositions for treatment of joint damage
RU2777504C2 (ru) Способы и композиции для лечения повреждения хряща и артрита
HK1260928A1 (en) Peptides and compositions for treatment of joint damage
HK1214754B (en) Peptides and compositions for treatment of joint damage

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241104

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241104

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250620

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251020

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251023

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251215

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251215